Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis.

Tocilizumab reduces the 2-year incidence of major adverse cardiovascular events by 4.3% in patients with giant cell arteritis compared to methotrexate.

• Why it matters: Giant cell arteritis increases cardiovascular risk due to systemic inflammation and vascular injury, but the impact of steroid-sparing therapies on these outcomes is unclear, necessitating investigation.
• What they did: A nationwide observational cohort study used the French National Health Data System to compare 1095 patients on tocilizumab with 902 on methotrexate, employing a target trial emulation approach to assess cardiovascular events over two years.
• The result: Initiation of tocilizumab was associated with a 40% lower risk of major adverse cardiovascular events, mainly driven by fewer coronary events and deaths, supporting its potential cardiovascular benefits in giant cell arteritis management.